Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Oncology
Vol. 4, Issue 2, 2017
October 26, 2016 EDT
A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Margaret Hux
,
Denise Zou
,
Esprit Ma
,
Peter Sajosi
,
Andreas Engstrom
,
Ross Selby
,
Eugene Benson
,
Andrew Briggs
,
Vijayveer Bonthapally
,
incremental cost-effectiveness ratio
quality-adjusted life year
chemotherapy
systemic anaplastic large cell lymphoma
brentuximab vedotin
cost-effectiveness
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9820
JHEOR
1.
Hux M, Zou D, Ma E, et al. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
JHEOR
. 2016;4(2):188-203.
doi:10.36469/9820
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats